AstraZeneca India Receives Approval for Expanded Imfinzi Indication
AstraZeneca Pharma India Limited announced on March 16, 2026, that it has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India, to import and distribute Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL, marketed as Imfinzi, for an additional indication.The approval allows for the treatment of patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior systemic therapy. This expanded indication paves the way for the marketing of Imfinzi in India, pending receipt of related statutory approvals.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.